...
首页> 外文期刊>The Australasian journal of dermatology >Severe cutaneous eruptions following the topical use of preparations containing bufexamac: Is it time to reconsider its registration in Australia?
【24h】

Severe cutaneous eruptions following the topical use of preparations containing bufexamac: Is it time to reconsider its registration in Australia?

机译:局部使用含Bufexamac的局部使用后的严重皮肤爆发:是时候重新考虑其在澳大利亚的注册时间?

获取原文
获取原文并翻译 | 示例
           

摘要

Despite being a well-recognised cause of allergic contact dermatitis with an embargo in many countries around the world, bufexamac is available over the counter in topical preparations in Australia. We present a series of patients who developed severe cutaneous eruptions after the topical application of bufexamac containing preparations to highlight the potential risks of this medication, as well as advocate for the reconsideration of its registration by the Therapeutic Goods Administration in Australia.
机译:尽管是全世界许多国家的禁运性过敏接触皮炎的经过公认的过敏性接触性,但Bufexamac可在澳大利亚的局部筹备工作中获得。 我们展示了一系列患者在Bufexamac含有制剂的局部应用后显影了严重的皮肤喷发,以突出这种药物的潜在风险,以及通过澳大利亚的治疗货物管理局进行重新考虑其注册。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号